Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Read More
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2025.
Read More
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Published: August 07, 2025 by: Fast Company
Sentiment: Positive
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used for weight loss, reached nearly $5.2 billion in revenue, up 68% from the same quarter last year and exceeding analyst estimates of $4.7 billion.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Read More
VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial
Published: August 07, 2025 by: Reuters
Sentiment: Negative
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy.
Read More
Hims & Hers: Still Growing After Breakup With Novo Nordisk
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding product offerings, and direct-to-consumer model support my positive outlook on the stock. HIMS's focus on recurring subscription revenue and high customer retention rates enhances long-term financial stability and growth potential.
Read More
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
Read More
Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
Published: August 06, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action.
Read More
Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S (NVO) Q2 2025 Earnings Conference Call August 6, 2025 7:00 AM ET Company Participants David S. Moore - Executive VP of US Operations & Member of Management Board Jacob Martin Wiborg Rode - Head of Investor Relations Karsten Munk Knudsen - Executive VP, CFO & Member of the Management Board Lars Fruergaard Jorgensen - President, CEO & Member of Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board Martin Holst Lange - Executive VP of Development & Member of the Management Board Maziar Mike Doustdar - Executive VP of …
Read More
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
Published: August 06, 2025 by: Investors Business Daily
Sentiment: Negative
Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, Wegovy.
Read More
Novo Nordisk expands legal action to protect patients from non-FDA approved weight-loss drugs
Published: August 05, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Brandon Gomez and Angelica Peebles join 'Power Lunch' to break down the biggest headlines in the pharmaceutical space.
Read More
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
Published: August 05, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo. Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
Novo Nordisk expands lawsuits against weight-loss drug compounders
Published: August 05, 2025 by: Reuters
Sentiment: Neutral
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic.
Read More
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: August 05, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”). Novo Nordisk is a pharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegat.
Read More
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Published: August 05, 2025 by: Schwab Network
Sentiment: Neutral
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily on its GLP-1 drugs sales.
Read More
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Published: August 05, 2025 by: Barrons
Sentiment: Negative
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options
Read More
Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A/S (NYSE: NVO) After Class Action Filing
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”) on behalf of investors who purchased or otherwise acquired publicly traded securities of Novo from May 7, 2025 through July 28, 2025 (the “Class Period”).
Read More
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Published: August 04, 2025 by: Investopedia
Sentiment: Positive
Novo Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leading Wall Street analysts to downgrade the stock.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo” …
Read More
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
Published: August 01, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S NVO Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors.
Read More
Novo Nordisk: Don't Miss Buying This Dip
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's 20%+ price drop since yesterday following a significant downgrade in sales and profit guidance is a great buying opportunity. The stock's forward P/E is at half the stock's five-year average, and with growth catalysts in place, fundamentals could improve too. The launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO.
Read More
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 23, 2025, Novo Nordisk announced that it was ending its partn.
Read More
Rosen Law Firm Encourages Novo Nordisk A/S Investors to Inquire About Securities Class Action Investigation – NVO
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novo Nordisk A/S (NYSE: NVO) resulting from allegations that Novo Nordisk may have issued materially misleading business information to the investing public. So What: If you purchased Novo Nordisk securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem.
Read More
Can Novo Nordisk's New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Published: July 30, 2025 by: WSJ
Sentiment: Neutral
The company's first non-Danish leader, Maziar Mike Doustdar, will face a challenging landscape in the U.S.
Read More
Novo Nordisk: After the profit warning what next?
Published: July 30, 2025 by: Proactive Investors
Sentiment: Negative
Shares in Novo Nordisk (NYSE:NVO) are under the spotlight after a surprise profit warning, which, while denting the share price, failed to the wreak the damage some might have feared. That said, the 3.6% fall in the stock piles on the pain for the Ozempic maker, which was formerly Europe's most valuable company.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406